Tim Jatkoe
University of Texas MD Anderson Cancer Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tim Jatkoe.
Journal of Clinical Oncology | 2008
Gauri R. Varadhachary; Dmitri Talantov; Martin N. Raber; Christina Meng; Kenneth R. Hess; Tim Jatkoe; Renato Lenzi; David R. Spigel; Yixin Wang; F. Anthony Greco; James L. Abbruzzese; J. D. Hainsworth
PURPOSE To evaluate the feasibility of a 10-gene reverse transcriptase polymerase chain reaction assay to identify the tissue of origin in patients with carcinoma of unknown primary (CUP) site. PATIENTS AND METHODS Diagnostic biopsy formalin-fixed, paraffin-embedded (FFPE) specimens from 120 patients with CUP were collected retrospectively from Sarah Cannon Research Institute, Nashville, TN, and prospectively from The University of Texas M. D. Anderson Cancer Center, Houston, TX. Tissue of origin assignments by the assay were correlated with clinical and pathologic features and with response to therapy. RESULTS The assay was successfully performed in 104 patients (87%), and a tissue of origin was assigned in 63 patients (61%). In the remaining 41 patients (39%), the molecular profiles were not specific for the six tumor types detectable by this assay. The tissues of origin most commonly identified were lung, pancreas, and colon; most of these patients had clinical and pathologic features consistent with these diagnoses. Patients with lung and pancreas profiles had poor response to treatment. Patients with colon cancer profiles had better response to colon cancer-specific therapies than they did to empiric CUP therapy with taxane/platinum regimens. Patients with ovarian cancer profiles were atypical, with widespread visceral metastases and a paucity of overt peritoneal involvement. CONCLUSION This gene expression profiling assay was feasible using FFPE biopsy specimens and identified a putative tissue of origin in 61% of patients with CUP. In most patients, the assigned tissue of origin was compatible with clinicopathologic features and response to treatment. Prospective studies in which assay results are used to direct therapy are indicated.
Journal of Clinical Oncology | 2004
Yixin Wang; Tim Jatkoe; Yi Zhang; Matthew G. Mutch; Dmitri Talantov; John Jiang; Howard L. McLeod; David Atkins
The Journal of Molecular Diagnostics | 2006
Dimitri Talantov; Jonathan Baden; Tim Jatkoe; Kristina Hahn; Jack Yu; Yashoda Rajpurohit; Yiqiu Jiang; Chang Choi; Jeffrey S. Ross; David Atkins; Yixin Wang; Abhijit Mazumder
Archive | 2012
Yixin Wang; Baoying Huang; Jack Yu; Yuqui Jiang; Tim Jatkoe; Yashoda Rajpurohit
Archive | 2012
Yixin Wang; Baoying Huang; Jack Yu; Yuqui Jiang; Tim Jatkoe; Yashoda Rajpurohit
Archive | 2010
Dmitri Talantov; Palma John F; Tim Jatkoe; Tatiana Vener; Yixin Wang; Haiying Wang
Archive | 2010
Dmitri Talantov; John F Palma; Tim Jatkoe; Tatiana Vener; Yixin Wang; Haiying Wang
Archive | 2010
Tim Jatkoe; John F Palma; Dmitri Talantov; Tatiana Vener; Haiying Wang; Yixin Wang; イーシン・ワン; ジョン・エフ・パルマ; タチアナ・ベナー; ティム・ジャトコウ; ドミトリー・タラントフ; ハイイン・ワン
Journal of Clinical Oncology | 2007
Gauri R. Varadhachary; Dmitri Talantov; Tim Jatkoe; Asif Rashid; Renato Lenzi; R. Chadha; J. Baden; Yixin Wang; James L. Abbruzzese; Martin N. Raber
Journal of Clinical Oncology | 2006
Dmitri Talantov; J. Baden; Tim Jatkoe; J. Yu; David Atkins; A. Mazumder; Yixin Wang